Aerial view of Lisbon, Portugal. Photo by Anton Zelenov.

The 44th Annual Meeting of the EBMT took place March 18-21, 2018, in Lisbon, Portugal.

UCART19 can bridge to transplant in adults

Print Friendly, PDF & Email


T cells
Image from NIAID
Preliminary data from a phase 1 trial suggest UCART19 can serve as a bridge to transplant in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). This “universal,” donor-derived, chimeric antigen receptor (CAR) T-cell therapy produced complete responses (CRs) in 6 of 9 patients treated. Five of the patients... [Read Article]
Print Friendly, PDF & Email

Phase 1 results with UCART19 in kids

Print Friendly, PDF & Email


Layla Richards, the first person
treated with UCART19
Photo courtesy of GOSH
Early results from a phase 1, pediatric trial of UCART19 expand upon results observed in children who received the therapy via a compassionate use program. Two patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) received UCART19, a “universal,” donor-derived chimeric antigen... [Read Article]
Print Friendly, PDF & Email

Mortality in patients with PTLD

Print Friendly, PDF & Email


Cell infected with Epstein-Barr
virus (green/red) among
uninfected cells (blue)
Image courtesy of
Benjamin Chaigne-Delalande
A review of recent studies has revealed a “significant burden” of mortality related to post-transplant lymphoproliferative disorder (PTLD), according to researchers. Of the 120 PTLD patients studied, 64% died and 42.5% died with PTLD. The median time from hematopoietic... [Read Article]
Print Friendly, PDF & Email

Kids may have higher rate of AdV infection after HSCT

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
Results of a large study revealed a higher incidence of adenovirus (AdV) infection after allogeneic hematopoietic stem cell transplant (allo-HSCT) in children than adults. The rate of AdV infection in the 6 months after allo-HSCT was 32% in children and 6% in adults. However, researchers believe this data... [Read Article]
Print Friendly, PDF & Email

AdV viral burden linked to mortality in kids

Print Friendly, PDF & Email


Transmission electron
micrograph of adenovirus
Image from CDC/
G. William Gary Jr.
Data from the AdVance study revealed a “strong correlation” between adenovirus (AdV) viral load and mortality in pediatric recipients of allogeneic hematopoietic stem cell transplant (allo-HSCT), according to researchers. The team found that patients with the highest AdV viral burden had roughly... [Read Article]
Print Friendly, PDF & Email

Manufactured graft deemed safe in blood cancer patients

Print Friendly, PDF & Email


Peripheral blood
stem cell graft
Phase 1 results suggest a programmed cellular therapy is safe for use in patients with hematologic malignancies. The therapy, ProTmune, is being developed as a next-generation allogeneic graft intended to reduce the incidence and severity of acute graft-versus-host disease (GVHD) after hematopoietic stem cell transplant (HSCT). Three of 7... [Read Article]
Print Friendly, PDF & Email

GPS consolidation may prolong PFS after ASCT

Print Friendly, PDF & Email


Guenther Koehne, MD, PhD
Photo courtesy of Baptist
Health South Florida
Post-transplant therapy including galinpepimut-S (GPS) may prolong progression-free survival (PFS) in patients with high-risk multiple myeloma (MM), according to new research. In a phase 2 trial, MM patients who received GPS and lenalidomide or bortezomib after autologous stem cell transplant (ASCT) had a... [Read Article]
Print Friendly, PDF & Email